Treatment of patients with steroid-refractory ulcerative colitis is still a challenge for physicians. A recent study has evaluated the effectiveness and safety of sequential rescue therapies in this subgroup of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Protic, M. et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J. Crohns Colitis http://dx.doi.org/10.1016/j.crohns.2014.05.004.
Dinesen, L. C. et al. The pattern and outcome of acute severe colitis. J. Crohns Colitis 4, 431–437 (2010).
Dignass, A. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J. Crohns Colitis 6, 991–1030 (2012).
Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380, 1909–1915 (2012).
Cottone, M. et al. Clinical course of ulcerative colitis. Dig. Liver Dis. 40 (Suppl. 2), S247–S252 (2008).
Mehta, S. J., Silver, A. R. & Lindsay, J. O. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment. Pharmacol. Ther. 38, 77–97 (2013).
Chaparro, M. et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment. Pharmacol. Ther. 35, 275–283 (2012).
Leblanc, S. et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am. J. Gastroenterol. 106, 771–777 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.G. receives honoraria for speaking from Abbvie, Ferring and MSD, and acts as a consultant for Hospira and Takeda. F.R. receives honoraria for speaking from Abbvie, Ferring and MSD, and acts as a consultant for Takeda.
Rights and permissions
About this article
Cite this article
Gionchetti, P., Rizzello, F. Sequential rescue therapy in steroid-refractory ulcerative colitis. Nat Rev Gastroenterol Hepatol 11, 521–523 (2014). https://doi.org/10.1038/nrgastro.2014.126
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.126
